Abstract
Objectives: The primary objective was to assess the prognostic significance of MR spectroscopy parameters (choline/NAA and choline/creatine ratio)both at Baseline (Pre operative MRS) and post adjuvant radiation regarding survival and its comparison with traditional anatomic MRI based grading parameters (enhancement quality, enhancement proportion, enhancement margin,T1 Flair Ratio).A secondary objective was to corelate any association between the MRS metabolic baseline and response values(cho/NAA and cho/creatine ) with Histopathologically proved recurrence.
Materials and Methods: 25 histopathologically proved Grade III gliomas (astrocytomas and mixed oligoastrocytomas),registered in our institution between 2013-2016 who had both preoperative and post radiation MRI and MRS done were included in the study.MRS metabolic parameters were graded at baseline (Pre op) into cho/Naa ratio (>3.5,<3.5)and cho/creatine ratio(>2,<2) and at response(post adjuvant radiation) into cho/Naa change(>25%,<25% of baseline) and Cho/creatine (>10%,<10% of baseline). Baseline Anatomic MRI characteristics of the tumor (pre op) was also graded into enhancement quality (mild/avid), proportional enhancement(>50%,<50%), Margin of enhancement(well defined/poorly defined) and T1/Flair Size ratio(expansive/infiltrative)based on the VASARI/REMBRANDT MR feature set. PFS was estimated from time of completion of adjuvant treatment to clinical or radiological progression or last clinical follow up. Univariate analysis using Kaplan maier survival method and Log Rank value test was done for both the metabolic MRS value groups (baseline and Response) and the anatomic MRI parameters. Univariate survival analysis was also done to assess significance of Radiation dose (>50 Gy, <50 Gy) and extent of surgery (total vs subtotal/biopsy). Any parameter with log rank p value<0.08 was deemed to be significant and was entered into multivariate cox regression analysis. Histopathologically confirmed cases of recurrence (positive HPE/negative HPE) was correlated with baseline and response MRS value groups using Paired t test to corelate any significance. All analysis were done using SPSS-V23.
Results: Median follow up period was 38 months &median pfs was 13.2 months. On univariate analysis of the baseline and response value groups of MRS, the most significant factor associated with better survival was cho/cr change greater than 10%(PFS of 22.1 months vs 9.3 months, log rank p value=0.002) followed by baseline cho/naa less than 3.5 (PFS of 21.7 months vs 12.7 months, p=0.021).Among the Anatomic MRI parameters well defined enhancement margin was associated with survival advantage(PFS 20.5 vs 12.3 months, p=0.045). Full RT dose and total excision both were individually associated with better survival (p=0.073 and p=0.002).On multivariate analysis only cho/cr change >10% was significant at p=0.144 among MRS parameters. Among the 7 patient who underwent rexcision following clinical/radiological progression,6 were HPE confirmed recurrence. On paired t test Cho/naa change>25% of baseline(post RT response value) was identified as the best predictor of HPE confirmed recurrence (p=0.008) better than radiological progression during Follow up(p=0.350)
Conclusion: MRS metabolic parameters (Lower baseline cho/naa and greater cho/cr change after treatment) are of significant survival advantage whereas lesser cho/Naa response has better specificity for HPE proved recurrence than its anatomic counterpart. Prospective studies evaluating voxel based MRS data incorporated into treatment planning systems can be an interesting way forward.
Keywords: Magnetic resonance spectroscopy, High grade gliomas, Adjuvant radiation, recurrence, progression free survival, radiotherapy planning
References
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system, Revised 4th ed. Lyon: IARC; 2016. pp. 10–122.
- Schmainda Diffusion-weighted MRI as a biomarker for treatment response in glioma
CNS Oncol. 2012 Nov; 1(2): 169–180.
- Quon, B. Brunet, A. Alexander et al., “Changes in serial magnetic resonance spectroscopy predict outcome in highgrade glioma during and after postoperative radiotherapy,” Anticancer Research, vol. 31, no. 10, pp. 3559–3565, 2011
- Boxerman JL, Ellingson BM. Response assessment and magnetic resonance imaging issues for clinical trials involving high-grade gliomas. Top Magn Reson Imaging 2015;24:127–36. doi: 10.1097/RMR.0000000000000054
- Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199–208.
- Ioanna Chronaiou, Anne Line Stensjøen, Torill Eidhammer Sjøbakk, Morteza Esmaeili & Tone Frost Bathen (2014) Impacts of MR spectroscopic imaging on glioma patient management, Acta Oncologica, 53:5, 580-589, DOI: 10.3109/0284186X.2014.891046
- Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, et al. MR-spectroscopy guided target delineation for highgrade gliomas. Int J Radiat Oncol Biol Phys. 2001; 50:915–28
- Thomas Pyka, Jens Gempt, Stefanie Bette, Florian Ringel and Stefan Förster, Positron emission tomography and magnetic resonance spectroscopy in cerebral gliomas, Clinical and Translational Imaging, 10.1007/s40336-017-0222-2,
- Ken et al: Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost,Radiation Oncology 2013, 8:1 http://www.ro-journal.com/content/8/1/1
- Wiki for the VASARI feature set The National Cancer Institute Web site.
- Suja Saraswathy et al, Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy J Neurooncol (2009) 91:69–81 DOI 10.1007/s11060-008-9685-3,
- Martin Bulika,b, Radim Jancaleka, c,∗, Jiri Vaniceka, b, Antonin Skocha,d, Marek Mechl e, Potential of MR spectroscopy for assessment of glioma grading, Clinica Neurology and Neurosurgery 115 (2013) 146–153
- Francesco Pignatti, et al, Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma, J Clinical Oncol 20:2076-2084. © 2002 by American Society of Clinical Oncology
- Prognostic factors in patients with WHO grade 3 gliomas: The Cleveland Clinic experience. Hashemi-Sadraei, H. S. Bawa, A. Satra, G. Rahmathulla, M. Patel, G. Stevens, T. M. Tekautz, L. A. Rybicki, D. M. Peereboom, J. H. Suh, R. Weil, M. A. Vogelbaum, G. Barnett, and M. S. Ahluwalia Journal of Clinical Oncology 2011 29:15_suppl, 2053-2053
- Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, et al. 18F-FDOPA PET/MRI fusion in patients with primary/ recurrent gliomas: initial experience. Eur J Radiol 2009;71:242–8
- Giese et al,Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment, J Clin Oncol 21:1624-1636. © 2003 by American Society of Clinical Oncology
- Belinda S. Y. Lia , Hao Wangb , Oded Gonena,*,Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy, Magnetic Resonance Imaging 21 (2003) 923–928
- Hattingen et al, 1 H MRSI and progression- free survival in patients with WHO grades II and III gliomas
- Tolia et al, Prognostic Value of MRS Metabolites in Postoperative Irradiated High Grade Gliomas, BioMed Research Internat-ional Volume 2015, Article ID 341042, http://dx.doi.org/10.1155/2015/341042
- Loni et al, Radiological Response Assessment in High Grade Gliomas: 3DCRT vs IMRT, JMSCR Vol||05||Issue||08||Page 26960-26965||August 2017
- Alexander, A. Murtha, B. Abdulkarim et al., “Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma,” Clinical and Investi-gative Medicine, vol. 29, no. 5, pp. 301–311, 2006.
- Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ: Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 2009, 91:69–81
- Galeffi F., Turner D. A. (2012). Exploiting metabolic differences in glioma therapy Drug Technol. 9,280–293. 10.2174/157016312803305906
- Clifford J. Belden, Pablo A. Valdes, Cong Ran, David A. Pastel, Brent T. Harris, Camilo E. Fadul, Mark A. Israel, Keith Paulsen, David W. Roberts, Radio Graphics Volume 31, Issue 6Oct 1 2011, https://doi.org/10.1148/rg.316115512
- W. Lee, B. A. Fraass, L. H. Marsh et al., “Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study,” International Journal of Radiation Oncology Biology Physics, vol. 43, no. 1, pp. 79–88, 1999.
- Narayana, J. Chang, S. Thakur et al., “Use of MR spectroscopy and functional imaging in the treatment planning of gliomas,” British Journal of Radiology, vol. 80, no. 953, pp. 347–354, 2007
- Tarnawski R, Sokol M, Pieniazek P, Maciejewski B, Walecki J, Miszczyk L and Krupska T: 1h-mrs in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys 52(5): 1271-1276, 2002.
- Ciernik et al, Radiation Treatment Planning With An Integrated Positron Emission And Computer Tomography (Pet/Ct): A Feasibility Study, Int. J. Radiation Oncology Biol. Phys., Vol. 57, No. 3, pp. 853–863, 2003
Corresponding Author
Dr Amitabha Manna
Assistant Professor, Department of Radiation Oncology, Medical College, Kolkata, India
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v6i11.136
